Chr. Hansen Holding A/S (CHYHY)
| Market Cap | 9.44B |
| Revenue (ttm) | 1.35B |
| Net Income (ttm) | 245.09M |
| Shares Out | 526.41M |
| EPS (ttm) | 0.47 |
| PE Ratio | 39.70 |
| Forward PE | 34.48 |
| Dividend | $1.01 (5.66%) |
| Ex-Dividend Date | Nov 24, 2022 |
| Volume | 20,460 |
| Open | 17.87 |
| Previous Close | 17.93 |
| Day's Range | 17.82 - 17.97 |
| 52-Week Range | 11.78 - 21.40 |
| Beta | 0.24 |
| Analysts | Hold |
| Price Target | 18.95 (+5.69%) |
| Earnings Date | Jan 12, 2023 |
About CHYHY
Chr. Hansen Holding A/S, a bioscience company, develops natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries in Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific. It operates through Food Cultures & Enzymes, and Health & Nutrition segments. The Food Cultures & Enzymes segment produces and sells various cultures, enzymes, and probiotic products that determine the taste, flavor, texture, shelf life, nutritional value, and health benefits of various consumer products ... [Read more]
Financial Performance
In 2022, CHYHY's revenue was 1.22 billion, an increase of 13.05% compared to the previous year's 1.08 billion. Earnings were 225.10 million, a decrease of -73.37%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for CHYHY stock is "Hold." The 12-month stock price forecast is $18.95, which is an increase of 5.69% from the latest price.
News
Chr. Hansen Holding A/S Interim Report Q1 2022/23
Statement by CEO Mauricio Graber: “The solid results for Q1 show the strength of our business model. Organic growth reached 10%, driven by both volume and pricing initiatives and EBIT b.s.i. increased...
Resolutions passed at the Annual General Meeting of Chr. Hansen Holding A/S
NOVEMBER 23, 2022 – ANNOUNCEMENT NO. 11
Chr. Hansen Holding A/S - Major shareholder announcement from APG Asset Management N.V.
Company announcement no. 6/2022 August 2, 2022
Chr. Hansen Holding A/S Interim Report Q3 2021/22
Company announcement no. 05/2022
Chr. Hansen Holding A/S Interim Report Q2 2021/22
Company announcement no. 03/2022
Chr. Hansen Holding A/S - Manager's transactions
Anders Mohr Christensen, Vice President Group Strategy & Investor Relations, Tel: +45 2515 2364
Chr. Hansen Holding A/S Interim report Q2 2020/21
Continued strong organic growth momentum leads to upwards narrowing of full-year organic growth guidance
Chr. Hansen Holding A/S Interim report Q1 2020/21
Company Announcement No. 01
Chr. Hansen Holding A/S Full-year report - Statement of results 2019/20
Company Announcement No. 23/2020
Chr. Hansen Holding A/S enters into a definitive agreement to divest its Natural Colors business to EQT
Chr. Hansen Holding A/S has today entered into an agreement to divest its Natural Colors business to the EQT IX Fund for a cash consideration of 800 EUR million on cash and debt free basis. The transa...
Chr. Hansen Holding A/S acquires Jennewein Biotechnologie GmbH to enter and lead the high-growth Human Milk Oligosaccharides market
Chr. Hansen Holding A/S (“Chr. Hansen”) has today entered into an agreement to acquire all of the shares of Jennewein Biotechnologie GmbH (“Jennewein”), which is a leading player in the Human Milk Oli...
UAS Laboratories LLC, a portfolio company of Lakeview Equity Partners, LLC, has been sold to Chr. Hansen Holding A/S
CHICAGO, July 28, 2020 /PRNewswire/ -- Lincoln International is pleased to announce that UAS Laboratories LLC, a portfolio company of Lakeview Equity Partners, LLC, has been sold to Chr. Hansen Holdin...
Chr. Hansen Holding A/S acquires UAS Laboratories LLC
Company Announcement No. 15/2020 - Chr. Hansen Holding A/S has today entered into an agreement with the owners of UAS Laboratories LLC (“UAS Labs”) to acquire 100% of the Wisconsin based B2B company s...